Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab

ABSTRACT: This phase II trial studies how well panitumumab and combination chemotherapy works in treating patients with metastatic colorectal cancer previously treated with combination chemotherapy and bevacizumab. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as leucovorin calcium, fluorouracil, and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving panitumumab and combination chemotherapy together may kill more tumor cells

DISEASE(S): Stage Iv Colon Cancer,Adenocarcinoma,Stage Iv Rectal Cancer,Signet Ring Adenocarcinoma Of The Rectum,Recurrent Colon Cancer,Rectal Neoplasms,Cystadenocarcinoma,Signet Ring Adenocarcinoma Of The Colon,Adenocarcinoma, Mucinous,Mucinous Adenocarcinoma Of The Colon,Recurrent Rectal Cancer,Colonic Neoplasms,Mucinous Adenocarcinoma Of The Rectum

PROVIDER: 2141822 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR